PH12021552036A1 - Substituted pyrrolopyridines as jak inhibitors - Google Patents
Substituted pyrrolopyridines as jak inhibitorsInfo
- Publication number
- PH12021552036A1 PH12021552036A1 PH1/2021/552036A PH12021552036A PH12021552036A1 PH 12021552036 A1 PH12021552036 A1 PH 12021552036A1 PH 12021552036 A PH12021552036 A PH 12021552036A PH 12021552036 A1 PH12021552036 A1 PH 12021552036A1
- Authority
- PH
- Philippines
- Prior art keywords
- alopecia
- jak inhibitors
- treatment
- substituted pyrrolopyridines
- pyrrolopyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842197P | 2019-05-02 | 2019-05-02 | |
| PCT/US2020/031332 WO2020223728A1 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552036A1 true PH12021552036A1 (en) | 2022-05-23 |
Family
ID=73017367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552036A PH12021552036A1 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as jak inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11420966B2 (enExample) |
| EP (1) | EP3962897A4 (enExample) |
| JP (1) | JP2022531088A (enExample) |
| KR (1) | KR20220004726A (enExample) |
| CN (1) | CN113727975A (enExample) |
| AU (1) | AU2020265828A1 (enExample) |
| BR (1) | BR112021021477A2 (enExample) |
| CA (1) | CA3138544A1 (enExample) |
| IL (1) | IL287717A (enExample) |
| MX (1) | MX2021013224A (enExample) |
| PH (1) | PH12021552036A1 (enExample) |
| SG (1) | SG11202108927UA (enExample) |
| WO (1) | WO2020223728A1 (enExample) |
| ZA (1) | ZA202105837B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102821964B1 (ko) | 2017-11-03 | 2025-06-19 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 |
| CN119080779A (zh) | 2018-08-10 | 2024-12-06 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| EP3939979A4 (en) * | 2019-03-14 | 2022-04-06 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| CN113200983B (zh) * | 2021-05-22 | 2023-01-03 | 中国药科大学 | 一种吡咯并吡啶结构的化合物、制备方法和医药用途 |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| CN120344524A (zh) * | 2022-12-02 | 2025-07-18 | 上海岸阔医药科技有限公司 | Jak抑制剂、药物组合物及治疗应用 |
| CN118459457A (zh) * | 2023-02-08 | 2024-08-09 | 南京羚诺生物医药技术研究院有限公司 | 一种吡咯并吡啶结构的化合物及其制备方法和用途 |
| CN118812508A (zh) * | 2023-04-07 | 2024-10-22 | 原研药港生命科学研究(辽宁)有限公司 | 1-异丙基-1h-吡唑类化合物及药物组合物和应用 |
| WO2025038910A1 (en) * | 2023-08-16 | 2025-02-20 | Aclaris Therapeutics, Inc. | Crystalline polymorph form a of a jak inhibitor and methods for its preparation |
| WO2025144781A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69422306T4 (de) | 1993-11-30 | 2000-09-07 | G.D. Searle & Co., Chicago | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
| PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| AR064879A1 (es) * | 2007-01-12 | 2009-04-29 | Astellas Pharma Inc | Compuesto de piridina condensado |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| WO2012058645A1 (en) * | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| SI3077395T1 (en) * | 2013-12-05 | 2018-03-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
| EP2924026A1 (en) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
| SG11201802961PA (en) * | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| ES2830446T3 (es) | 2015-12-11 | 2021-06-03 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Derivado de azetidina, método de preparación del mismo y uso del mismo |
| TW201811795A (zh) | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
| WO2019090143A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| KR102821964B1 (ko) | 2017-11-03 | 2025-06-19 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 |
| CN119080779A (zh) | 2018-08-10 | 2024-12-06 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| EP3939979A4 (en) * | 2019-03-14 | 2022-04-06 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
-
2020
- 2020-05-04 CA CA3138544A patent/CA3138544A1/en active Pending
- 2020-05-04 AU AU2020265828A patent/AU2020265828A1/en not_active Abandoned
- 2020-05-04 SG SG11202108927UA patent/SG11202108927UA/en unknown
- 2020-05-04 JP JP2021561745A patent/JP2022531088A/ja active Pending
- 2020-05-04 WO PCT/US2020/031332 patent/WO2020223728A1/en not_active Ceased
- 2020-05-04 KR KR1020217039379A patent/KR20220004726A/ko not_active Withdrawn
- 2020-05-04 CN CN202080023588.6A patent/CN113727975A/zh active Pending
- 2020-05-04 MX MX2021013224A patent/MX2021013224A/es unknown
- 2020-05-04 US US16/866,182 patent/US11420966B2/en active Active
- 2020-05-04 EP EP20798983.1A patent/EP3962897A4/en not_active Withdrawn
- 2020-05-04 PH PH1/2021/552036A patent/PH12021552036A1/en unknown
- 2020-05-04 BR BR112021021477A patent/BR112021021477A2/pt not_active Application Discontinuation
-
2021
- 2021-08-16 ZA ZA2021/05837A patent/ZA202105837B/en unknown
- 2021-10-31 IL IL287717A patent/IL287717A/en unknown
-
2022
- 2022-06-30 US US17/809,984 patent/US20220372034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202105837B (en) | 2022-07-27 |
| SG11202108927UA (en) | 2021-09-29 |
| CN113727975A (zh) | 2021-11-30 |
| US20200347053A1 (en) | 2020-11-05 |
| US11420966B2 (en) | 2022-08-23 |
| JP2022531088A (ja) | 2022-07-06 |
| US20220372034A1 (en) | 2022-11-24 |
| EP3962897A1 (en) | 2022-03-09 |
| AU2020265828A1 (en) | 2021-09-09 |
| BR112021021477A2 (pt) | 2021-12-21 |
| WO2020223728A1 (en) | 2020-11-05 |
| KR20220004726A (ko) | 2022-01-11 |
| EP3962897A4 (en) | 2022-12-14 |
| IL287717A (en) | 2021-12-01 |
| MX2021013224A (es) | 2022-01-06 |
| CA3138544A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552036A1 (en) | Substituted pyrrolopyridines as jak inhibitors | |
| PH12020550499A1 (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| JOP20240084A1 (ar) | مركبات الكينولين كمثبطات لـ kras | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| PH12019502436A1 (en) | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| BR112016012734A8 (pt) | composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto | |
| NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
| EA201791941A1 (ru) | Бициклические кетосульфонамидные соединения | |
| BR112013028430A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto | |
| MY178660A (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
| MX2016012480A (es) | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| NZ598144A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| CY1121060T1 (el) | Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση | |
| MX394882B (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) | |
| BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
| BR112018014957A2 (pt) | compostos e composições para o tratamento de criptosporidiose |